For research use only. Not for therapeutic Use.
BET-IN-19 (Compound 146) is a BET inhibitor. BET-IN-19 inhibits hlL-6 mRNA transcription (IC50 ≤ 0.3 uM), and c-myc activity in human AML MV4-11 cell (IC50 ≤ 0.3 uM)。BET-IN-19 inhibits tetra-acetylated histone H4 binding to BRD4 bromodomain 1 (IC50 ≤ 0.3 uM)[1].
| Catalog Number | I040634 |
| CAS Number | 1643947-30-1 |
| Synonyms | 1-benzyl-6-(3,5-dimethyl-1,2-oxazol-4-yl)-N-methylimidazo[4,5-b]pyridin-2-amine |
| Molecular Formula | C19H19N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H19N5O/c1-12-17(13(2)25-23-12)15-9-16-18(21-10-15)22-19(20-3)24(16)11-14-7-5-4-6-8-14/h4-10H,11H2,1-3H3,(H,20,21,22) |
| InChIKey | VUFGOHIETLJZRG-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=NO1)C)C2=CC3=C(N=C2)N=C(N3CC4=CC=CC=C4)NC |
| Reference | [1]. Bryan Cordell DUFFY, et al. Novel bicyclic bromodomain inhibitors. Patent. WO2015002754 A2. |
